CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

NSAIDs Increase Cardiovascular Risk in Osteoarthritis

Published: Fri, 15 Jun 2018 16:46:44 EDT
Nonsteroidal anti-inflammatory drugs contribute to the elevated risk for cardiovascular disease in people with osteoarthritis, new research shows, but alternatives for pain management are limited.
Medscape Medical News

Fourth EAN Meeting Tackles Theme of Neurogenetics

Published: Fri, 15 Jun 2018 16:45:10 EDT
New insights into genetic influences on brain disorders are emerging every day, says the president of the European Academy of Neurology.
Medscape Medical News
Displaying results 19-20 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Consolidate pRED and gRED R&D units? ‘No way,’ says Roche CEO

Published: Tue, 12 Jun 2018 12:06:00 +0000
Like just about all its peers in the pharma sector, Roche has been trying to find ways to reduce the costs of R&D—but CEO Severin Schwann won’t contemplate doing so by consolidating its Swiss-led research operations with those of subsidiary Genentech.

Lilly, AstraZeneca halt phase 3 Alzheimer’s trials for futility, further denting BACE prospects

Published: Tue, 12 Jun 2018 09:03:01 +0000
Eli Lilly and AstraZeneca have pulled the plug on two phase 3 trials of BACE inhibitor lanabecestat in Alzheimer’s disease. The partners stopped the studies after an independent interim analysis deemed they were destined to fail.

BridgeBio spins out ultrarare genetic disease company after acquiring enzyme from Alexion

Published: Mon, 11 Jun 2018 14:58:49 +0000
Through an agreement with Alexion Pharmaceuticals, BridgeBio Pharma acquired a synthetic enzyme replacement therapy for an ultrarare, fatal genetic disease that causes seizures in infants. A new spinout, Origin Biosciences, will handle development.
Displaying results 19-21 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top